145 related articles for article (PubMed ID: 33480036)
1. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Jain MR
Drug Dev Res; 2021 Sep; 82(6):852-860. PubMed ID: 33480036
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Jain M; Joharapurkar A; Patel V; Kshirsagar S; Sutariya B; Patel M; Patel H; Patel PR
Eur J Pharmacol; 2019 Jan; 843():113-120. PubMed ID: 30458168
[TBL] [Abstract][Full Text] [Related]
3. HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.
Patel VJ; Joharapurkar A; Kshirsagar SG; Patel MS; Savsani HH; Dodiya HS; Rakhasiya MH; Kajavadara C; Valani D; Jain MR
Toxicol Appl Pharmacol; 2024 Feb; 483():116832. PubMed ID: 38266872
[TBL] [Abstract][Full Text] [Related]
4. Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.
Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Kajavadara C; Valani D; Jain MR
Curr Res Pharmacol Drug Discov; 2022; 3():100102. PubMed ID: 35570856
[TBL] [Abstract][Full Text] [Related]
5. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Kato S; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
[TBL] [Abstract][Full Text] [Related]
6. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Patel H; Modi N; Chaudhari J; Patel P; Giri P; Patel H; Pandya V; Desai R; Jain M
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):725-740. PubMed ID: 35881329
[TBL] [Abstract][Full Text] [Related]
8. Desidustat: First Approval.
Dhillon S
Drugs; 2022 Jul; 82(11):1207-1212. PubMed ID: 35834123
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice.
Santana AC; Degaspari S; Catanozi S; Dellê H; de Sá Lima L; Silva C; Blanco P; Solez K; Scavone C; Noronha IL
Nephrol Dial Transplant; 2013 May; 28(5):1140-9. PubMed ID: 23345625
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.
Parmar DV; Kansagra KA; Patel JC; Joshi SN; Sharma NS; Shelat AD; Patel NB; Nakrani VB; Shaikh FA; Patel HV;
Am J Nephrol; 2019; 49(6):470-478. PubMed ID: 31112954
[TBL] [Abstract][Full Text] [Related]
11. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation.
Hu L; Yang C; Zhao T; Xu M; Tang Q; Yang B; Rong R; Zhu T
J Surg Res; 2012 Jul; 176(1):260-6. PubMed ID: 21816412
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effect of Nesfatin-1 in Adenine-Induced Chronic kidney Disease: An in vitro and in vivo study.
Panditrao Lahane G; Dhar A
Biochem Pharmacol; 2024 Jul; 225():116284. PubMed ID: 38750903
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
[TBL] [Abstract][Full Text] [Related]
15. Curcumin Ameliorates Kidney Function and Oxidative Stress in Experimental Chronic Kidney Disease.
Ali BH; Al-Salam S; Al Suleimani Y; Al Kalbani J; Al Bahlani S; Ashique M; Manoj P; Al Dhahli B; Al Abri N; Naser HT; Yasin J; Nemmar A; Al Za'abi M; Hartmann C; Schupp N
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):65-73. PubMed ID: 28561324
[TBL] [Abstract][Full Text] [Related]
16. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
[TBL] [Abstract][Full Text] [Related]
17. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
Li L; Nakano D; Zhang A; Kittikulsuth W; Morisawa N; Ohsaki H; Suzuki N; Yamamoto M; Nishiyama A
J Pharmacol Sci; 2020 Dec; 144(4):229-236. PubMed ID: 33070842
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydrocurcumin protects against sepsis-induced acute kidney injury via the SIRT1 pathway.
Li L; Liu X; Li S; Wang Q; Wang H; Xu M; An Y
Ren Fail; 2021 Dec; 43(1):1028-1040. PubMed ID: 34187277
[TBL] [Abstract][Full Text] [Related]
19. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease.
Qian FY; Li ZL; Guo YD; Gao HC; Gu LH; Le K; Xie CM; Wang B; Zhang ZJ
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1265-F1273. PubMed ID: 31588798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
